zebra fish

Biobide signs a contract with the U.S. National Institute of Environmental Health Sciences (NIH-NIEHS)

This project will analyze the toxicological impact of exposure to 30 chemical compounds using zebrafish as animal model.

The NIEHS is one of the 27 Institutes and Centers composing the US-National Institutes of Health.

January 25, 2016. BBD BioPhenix-Biobide (now part of Bionaturis Group), has recently signed a contract agreement with one of the U.S. National Institutes of Health, the National Institute of Environmental Health Sciences (NIH-NIEHS), for analyzing the impact of exposure to different chemicals with unknown toxicological potential in zebrafish embryos. Biobide provides zebrafish-based services in the preclinical area, mainly toxicology, through early detection of adverse effects in a Good Laboratory Practice (GLP) setting.

Biobide will perform the assessment of bioavailability and toxicity in zebrafish embryos following exposure to 30 compounds with potential for various adverse effects, providing high content screening information on multiple target organs using a GLP-environment.

This contract agreement between Biobide and one of the main Institutions of Public Health in the USA, the NIH, is the result of years of preparation and study. BBD BioPhenix-Biobide, is one of the recognized zebrafish resource institutions worldwide. “This contract agreement becomes relevant because it may facilitate future collaborations with this prestigious institution”, the R&D Management Director at the company, Arantza Muriana, has stated.

The collaboration between Biobide and the NIH-NIEHS started last year when they collaborated in a project to study the toxicity of several flame retardants found in everyday household products, such as utensils, upholstery and furniture, to which people, and most importantly babies and young children, are regularly exposed.  Biobide and the NIH-NIEHS utilized the versatility of the zebrafish model to evaluate the toxicity of environmental compounds with the main goal of the assay being the reduction or prevention of the use of such […]

January 25th, 2016|Blog english, Press Releases|Comments Off|

Bionaturis Group enhances its international alliances in San Diego (USA)

Bionaturis and BBD Biophenix have taken part in the latest edition of Bio International Convention 2014, in San Diego (June 2014), where the hard-working days have strengthened the international strategies and alliances of the group.

Along three days, the delegates moved to San Diego, Juan Jose Infante (Bionaturis) and Arantza Muriana (BBD Biophenix), has had up to 60 high-level ‘One to One’ meetings, mixing follow-up meetings with already pharmaceutical and veterinarian clients with the evaluation of development opportunities with new ones. The managers of both companies in the Convention have stated: “They have been more than fruitful meetings to consolidate our relationships with current and future partners and to confirm how our join innovative portfolio is at the forefront of the industry, so that we expect to sign new contracts shortly”.

In particular, Bionaturis´ attention has been focused on its portfolio of biological products and the unique features of its FLYLIFE platform as well, whereas BBD has validated the relevance of zebra fish as animal model for increasing the screening success rate not only for the pharmaceutical sector but also for petrochemical, agrochemical, nutraceutical and cosmetics ones.

The Convention in San Diego has also provided a great opportunity to go further within the global expansion plan, with M&As and international growth in Asia and LATAM as  cornerstones.

Expositor

This year Bionaturis Group has participated as exhibitor within the Spanish pavilion, having a booth sponsored by Biobasque. The dynamism shown in this Convention and the record number of partnering meetings is a prove of a wealthy sector with high potential growth. The event showcased the official presentation of Bionaturis Group, after the recent acquisition of BBD Biophenix.

July 4th, 2014|Blog english, Press english|Comments Off|

Bionaturis acquires BBD BIOPHENIX S.L.

Bionaturis (ticker BNT-MAB), an international reference company developing biological drugs, has just acquired the San Sebastian-based company BBD BIOPHENIX S.L (BBD), a leader in state-of-the-art screening systems for drug discovery. With this acquisition Bionaturis incorporates cutting-edge biotech assets to its organic growth, in this case, related to the use of zebra fish models for early determination of drug pharmacological profiles.

BBD is an international leader in the field of using the zebra fish model for drug toxicity and efficacy tests applying the latest technologies such as image analysis and automation. This alternative model improves the cost/effectiveness of preclinical phase for pharmaceutical, biotechnology, petrochemical, agrochemical, and cosmetic companies. BBD has a wide portfolio of big pharma clients, from United States and Europe.

About the acquisition, Victor Infante –Bionaturis´ CEO- states: “This acquisition is important to the growth of Bionaturis, improving its services and clients portfolio at international level, but above all, it means to add talent on board. The intrinsic talent of BBD is a reference of leadership and result-achievement”.

Arantza Muriana, R & D Director and founding partner of BBD BioPhenix comments on the operation: “It will help us meet the goals of market diversification and international expansion marked by the company”. She also highlights the important synergies between the two companies.

 

Strategic value

It´s a strategic acquisition for Bionaturis to support its growth and international expansion, at the time that contributes to its vision of facilitating industry the drug development process. With this operation, Bionaturis extends its international presence and multinational customers portfolio. For BBD, which will keep its headquarters in San Sebastian, it also represents a great opportunity for the fulfillment of its expansion and diversification plan.

 

About BBD BIOPHENIX

BBD BioPhenix is a Contract Research Organization (CRO) that […]

Uso de cookies

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.

CERRAR